RE: MTFB16 May 2020 14:08
Correct, and I think it's more accurate to say that the FDA simply want an understanding of any liver problems before they could approve - nothing else held them back. Because the liver is involved in detoxifying pretty much everything that enters your bloodstream, there are millions of things that 'excite' the liver and cause temporary changes in its biochemistry, but that doesn't mean they are long-term dangerous at the right doses. And, even with slight risk, the benefits may easily outweigh the costs. Best case scenario IMO is if someone sees value in a re-application for Iclaprim, not for skin infections, but for lung infections. The process could take a while (or, with the COVID situation, perhaps not too long) and, pending approval, I wouldn't be surprised if the SP bounced around the 20-30p mark, as it used to do back in the day (mind you, it's fluctuations were baffling even then...) As I say, best case ... but it would certainly explain the presence of the basher army .